v3.25.2
Stockholders’ Equity (Tables)
 6 Months Ended
Jul. 04, 2025
Share-Based Payment Arrangement [Abstract]  
Schedule of Allocated Stock-Based Compensation
We allocated the stock-based compensation for our 2017 Plan and our 2000 Employee Stock Purchase Plan (as amended and restated, the Amended ESPP) as follows (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2025202420252024
Research and development$14,143 $9,178 $23,665 $13,070 
Selling, general and administrative21,928 16,176 38,336 31,397 
Total stock-based compensation
$36,071 $25,354 $62,001 $44,467 
Stock-based compensation for each type of award under our 2017 Plan and Amended ESPP were as follows (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2025202420252024
Stock options$671 $1,524 $1,731 $3,262 
Restricted stock units34,626 22,164 57,728 37,598 
Performance stock units— 1,097 241 1,824 
Employee stock purchase plan
774 569 2,301 1,783 
Total stock-based compensation
$36,071 $25,354 $62,001 $44,467 
Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions
We used a Monte Carlo simulation model and the following assumptions to determine the grant date fair value of $47.58 per share for the 2025 TSR-based RSUs and $25.10 per share for the 2025 stock price target-based RSUs:
2025 TSR-based RSUs2025 stock price target-based RSUs
Fair value of Exelixis common stock on grant date
$37.53 $36.92 
Expected volatility
32.6 %38.3 %
Risk-free interest rate
4.0 %3.9 %
Dividend yield
— %— %